Treating donor mice with rhIL-11 and rhG-CSF promotes transplant-tolerance and preserves the effects of GVL after allogeneic bone marrow transplantation.
We investigated the impact of recombinant human interleukin-11 (rhIL-11) and granulocyte colony-stimulating factor (rhG-CSF) on bone marrow transplantation. Treatments for leukemic mice were (A) no treatment, (B) mock transplantation, and transplantation from the following donors: (C1) syngeneic, (C) controls, (D) rhG-CSF treated, (E) rhIL-11 treated, and (F) rhIL-11 and rhG-CSF treated. Graft-versus-host disease incidences were 100%, 60%, 78%, and 30% in C, D, E, and F, respectively. The 30 d leukemia-free survival improved significantly in F (70%) compared to C (0%), D (40%), and E (20%) (P<0.01). Thus, treating donor mice with rhIL-11 and rhG-CSF promoted transplant-tolerance and recipient survival.
Huang
Xiao-Jun
XJ
Peking University People's Hospital & Peking University Institute of Hematology, No. 11, Xizhimen South Street, Beijing 100044, China. xjhrm@medmail.com.cn
Zhao
Jie
J
Zhao
Xiang-Yu
XY
Chang
Ying-Jun
YJ
D000818:Animals; D016026:Bone Marrow Transplantation; D020544:Graft vs Leukemia Effect; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D017370:Interleukin-11 / Q000494:pharmacology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D011994:Recombinant Proteins / Q000494:pharmacology
D017370:Interleukin-11; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor